ROSEN, A LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FATE
February 08, 2023 17:22 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2,...
Class Action Deadlines: Y-mAbs Therapeutics, Bioventus Inc, Fate Therapeutics, Inc, and Invivyd Inc – Contact Johnson Fistel
February 07, 2023 10:57 ET
|
Johnson Fistel, LLP
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that class action lawsuits have commenced on behalf of investors of Y-mAbs Therapeutics, Inc....
Investors who hold shares of Fate Therapeutics, Inc. (NASDAQ: FATE) Long should contact the Shareholders Foundation in connection with a Lawsuit filed against Fate Therapeutics, Inc.
February 07, 2023 10:15 ET
|
Shareholders Foundation, Inc.
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Fate Therapeutics, Inc. (NASDAQ: FATE). ...
DEADLINE ALERT for FATE, SHC, ARBK, and EYE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
February 03, 2023 14:00 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
DEADLINE ALERT for YMAB, FATE, and SHC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
January 27, 2023 14:33 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Lowey Dannenberg Notifies Fate Therapeutics Inc. (NASDAQ: FATE) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
January 23, 2023 10:56 ET
|
Lowey Dannenberg, P.C.
WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit...
Fate Therapeutics Shareholder Investigation: Submit Your Losses to Johnson Fistel
January 06, 2023 09:35 ET
|
Johnson Fistel, LLP
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate” or the “Company), any of its...
FATE Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Potential Securities Claims Against Fate Therapeutics, Inc.
January 05, 2023 20:00 ET
|
Wohl & Fruchter LLP
MONSEY, N.Y., Jan. 05, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Fate Therapeutics, Inc. (Nasdaq: FATE) (“FATE”) violated federal securities laws in...
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
January 05, 2023 17:00 ET
|
Fate Therapeutics, Inc.
Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction Advancing...
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
December 13, 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...